

ONCOLOGY



Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology.

Our Oncology Partnering Focus

We are seeking in-licensing and collaborative opportunities at discovery, pre-clinical and clinical stages, for therapeutic programs in our interest areas.

Cancer cell-directed therapies:

- Growth signaling e.g. RTKs, Wnt, Notch, KRAS, MET, MYC
- Regulation of cell death
- Epigenetic regulation
- Regulation of protein homeostasis
- DNA damage control pathways

Immune cell-directed therapies:

- Myeloid cell-modulating therapies
- Tumor stromal concepts and targets
- Cancer vaccines and oncolytic viruses
- Novel tumor antigen identification platforms, including neoantigens

Contact:

Dr. Oliver Kast

oliver.kast@boehringer-ingelheim.com

Dr. Scott DeWire

scott.dewire@boehringer-ingelheim.com

Dr. Emilio Erazo-Fischer

emilio.erazo-fischer@boehringer-ingelheim.com

Dr. Maria Antonietta Impagnatiello

maria_antonieta.impagnatiello@boehringer-ingelheim.com